Brief: TOT Biopharm International Says Revenue Increased To RMB442,178 Thousand For Year
17/03/2023 01:13
March 17 (Reuters) - TOT BIOPHARM International Co Ltd
1875.HK :
* REVENUE INCREASED BY 479% YEAR- ON-YEAR TO RMB442,178
THOUSAND
FOR YEAR
* IN 2022, NET LOSS NARROWED BY 81% YEAR-ON- YEAR TO
RMB50,046
THOUSAND
Further company coverage: 1875.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29